thermo cream, page-16

Although some of your specifics are slightly out, its not that important. How it works is for scientists to understand, and even they didnt understand it in its original form.

All the products in this market segment will have slight differences in how its applied, the active ingredients, allergic reactions, duration of relief, etc.

What works for one person can be a total failure on another. And vice versa.

Its not as important a segment as HIV/Aids or cancer or even Biota and the various influenza strains. But its a large segment and a growing segment as the population ages.

The market is certainly big enough for multiple players with multiple product lines.

But I do agree with you regarding the risk factors.

PNO are moving to distribution phase. Its very expensive. Many fixed costs including payments to Crossmark and advertising.

IF the product doesnt sell in numbers, PNO will make a large loss and be left without money or a viable product. Then its back to square one.

Ofcourse their would be product extensions and Tripeptofen to follow, but CR would need to fund that if Thermalife fails.

As an investment, if Thermalife fails then so does PNO IMO.

But if Thermalife succeeds, then the extensions should succeed as they are related. And they will be self funded.

So high risk but VERY high reward IMO.